Forest Labs Announces Added Settlement Deal in BYSTOLIC Patent Litigation

Forest Laboratories, Inc. (NYSE: FRX) and Forest Laboratories Holdings, Ltd.(collectively, "Forest") announced today that they have entered into asettlement agreement with Glenmark Generics Inc., USA, Glenmark Generics Ltd.,and Glenmark Pharmaceuticals Ltd. (collectively, "Glenmark") in patentinfringement litigation brought by Forest in response to Glenmark'sabbreviated new drug application (ANDA) seeking approval to market genericversions of Forest's BYSTOLIC® (nebivolol) tablets. This settlement agreementis in addition to the previously announced BYSTOLIC® patent infringementsettlement agreements with Hetero Labs Ltd., Alkem Laboratories, Ltd.,Indchemie Health Specialties Pvt. Ltd., and Torrent Pharmaceuticals Ltd.Specifically, under the terms of the settlement agreement and subject toreview of the settlement terms by the U.S. Federal Trade Commission, Forestwill provide a license to Glenmark that will permit it to launch its genericversions of BYSTOLIC® as of the date that is the later of (a) three calendarmonths prior to the expiration of U.S. Patent No. 6,545,040, including anyextensions and/or pediatric exclusivities or (b) the date Glenmark receivesfinal FDA approval of its ANDA, or earlier in certain circumstances. Similarpatent infringement litigation brought by Forest against AmerigenPharmaceuticals Ltd. and Watson Pharmaceuticals Inc., and related companiesand subsidiaries thereof, remains pending in a multidistrict litigationestablished in the U.S. District Court for the Northern District of Illinois.